The relevance of the Mometasone furoate nasal spray in clinical practice

G Ciprandi, A Varricchio

Article ID: 5207
Vol 32, Issue 4, 2018
DOI: https://doi.org/10.54517/jbrha5207
Received: 8 September 2018; Accepted: 8 September 2018; Available online: 8 September 2018; Issue release: 8 September 2018

Abstract

Allergic rhinitis (AR) is characterized by mucosal inflammation, therefore anti-inflammatory drugs are indicated for its treatment, mainly concerning intranasal administration. Mometasone furoate nasal spray (MFNS) has been on the market under the brand Nasonex® for 20 years and has high effectiveness and an excellent safety profile. From a clinical point of view, an ideal topical medication should respect a series of requirements, including handy device, good sensory characteristics, aptitude to the reach posterior nasal cavity, long residence time, and optimal pharmacokinetic and pharmacodynamic activities. MFNS fully satisfies these claims, as underlined by 20 years of worldwide prescriptions.


Keywords

allergic rhinitis;intranasal corticosteroids;mometasone furoate;nasal spray;device


References

Supporting Agencies



Copyright (c) 2018 G Ciprandi, A Varricchio




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).